ClearMains
Takeda’s two-dose QDENGA vaccine, approved by the Drug Controller General of India, can be administered without prior dengue screening and is designed to protect against all four dengue virus serotypes
Quick Revision
Prelims-testable facts
Trap alerts
Mains Practice Question
Critically examine the implications of approving a two-dose dengue vaccine for individuals aged 4 to 60 years on public health infrastructure and preparedness in India.
250 words
Practice this in the exam hall →Prelims Practice MCQs
Takeda's two-dose QDENGA vaccine has been approved by which authority?
The Drug Controller General of India has approved the Takeda's two-dose QDENGA vaccine, marking a significant milestone in India's public health landscape.
How many doses of the Takeda's QDENGA vaccine are required for full protection?
The QDENGA vaccine is a two-dose regimen, administered without prior dengue screening.
What is the age range for which the Takeda's QDENGA vaccine has been approved?
The QDENGA vaccine has been approved for individuals aged 4 to 60 years, marking a significant expansion of vaccination coverage in India.
Consider the following statements regarding Dengue Vaccine Approval: 1. The Drug Controller General of India approved Takeda's two-dose QDENGA vaccine on July 20, 2025. 2. Takeda's two-dose QDENGA vaccine is the first dengue vaccine to be approved in India for individuals aged 4 to 60 years. 3. The QDENGA vaccine requires prior dengue screening before administration. How many of the above statements are correct?
Statement 1 is incorrect because the approval was granted on July 20, 2026. Statement 2 is correct because Takeda's two-dose QDENGA vaccine is indeed the first dengue vaccine to be approved in India for individuals aged 4 to 60 years. Statement 3 is incorrect because the fact list states that the QDENGA vaccine can be administered without prior dengue screening.
Consider the following two statements: Statement-I: Takeda's two-dose QDENGA vaccine has been approved by the Drug Controller General of India. Statement-II: The approval was granted because Takeda's two-dose QDENGA vaccine is designed to protect against all four dengue virus serotypes. Which one of the following is correct in respect of the above statements?
Statement 1 is correct because it directly states that the Drug Controller General of India approved Takeda's two-dose QDENGA vaccine. Statement 2 is incorrect because while the QDENGA vaccine does protect against all four dengue virus serotypes, this fact does not explain why it was approved.